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Several epidemiological studies have reported high prevalence of HBsAg among pregnant women in Burkina Faso. They used 
various algorithms, as it is also done for the routine diagnostic. Knowing this antigen carriage rate in such a population or in 
other clinic attendees is important for the implementation of a national immunisation programme and the monitoring of 
patients with hepatitis B. Often, the screening tests were not confirmed in spite of the existence of known false positive and 
false negative results. The aim of this study was to determine a more accurate prevalence of HBsAg, among the pregnant women 
in Burkina Faso. From October 2006 to January 2007, blood samples were collected from 1139 pregnant women.  Each sample 
was analyzed for HBsAg, using two assays and according to manufacturers’ instructions vis,  Hepanostika®HBsAg Uniform II 
B9 (Bio-Mérieux; France) and HBsAg (V2) Abbott AxSYM® system (Abbott Diagnostics).  All the positive samples were tested 
with a confirmatory neutralization assay- Hepanostika®HBsAg Uniform II B9 Confirmatory (Bio-Merieux). The mean age of the 
pregnant women was 24.85years [range: 15-45years] and the age range of 20-24 (37%) and 25-29 (25.4%) years were the most 
represented. The overall rate of HBsAg-positive pregnant women with the two screening assays was 20.9%. The HBsAg 
detection rate was significantly higher with Hepanostika® UniformII B9 (16.9%) than with HBsAg (V2) AxSYM system assay 
(12.1%), with P<0,0001. The general seroprevalence of HBsAg was 9% after the confirmatory neutralization testing, with 56.7% 
of false positive results: this difference was statistically significant (P<0.0001). The rate of HBsAg positive pregnant women was 
higher in the age range of 25-29years than in the others; however, this difference was not statistically significant. In an 
epidemiological approach, the results found in this study confirmed the Burkina Faso belonging to the high endemic carriage 
area for HBsAg. The results showed that in an individual approach, the confirmatory assay is necessary and there is a need to 
implement more accurate algorithm for the routine diagnostic in patients.   
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INTRODUCTION 
Hepatitis B virus (HBV) infection is a global health 
problem. The World Health Organization (WHO) 
estimates that more than 2 billion people worldwide 
have been infected with HBV. Of these, 
approximately 360 million individuals are chronically 
infected, and each year acute and chronic infections 
cause 500,000 to 1.2 million deaths (1). Among these 
360 million people in the world chronically infected 
with HBV, 65 million reside in Africa and of the 1.2 
million deaths due to HBV related diseases recorded 
annually throughout the world, approximately 
250,000 occur in Africa (2- 4).  
The endemicity of hepatitis B is defined according to 
the prevalence of the hepatitis B surface antigen 
(HBsAg) in the general population of geographical 
areas, and it varies considerably globally: HBsAg 
prevalences of >8% are typical of highly endemic 
areas, prevalences of 2–8% are found in areas of 
intermediate endemicity, whereas in areas with low 
endemicity less than 2% of the population is HBsAg-
positive (1). In Africa, the rate of HBsAg carriage in 
the general population ranges up to 20% (2), and 
three levels of endemicity exist also, as measured by 
the prevalence of HBsAg: hepatitis B virus is 
hyperendemic in sub-Saharan Africa (>8%), with the 
exception of a few countries which constitute areas of 
intermediate endemicity (2–8%), and regions of low 
endemicity (<2%) in the northern African countries. 
However, in the late area, pockets of high endemicity 
can occur within these countries (4).  
 
The HBsAg is also used for the screening of hepatitis 
B in pregnant women. Currently, in the countries 
having national programmes against hepatitis B, 
notably in pregnant women, HBsAg is the main 
serologic marker recommended by the guidelines for 
the detection of maternal HBV infection (5-8). HBsAg 
can be assessed by various assays in clinical 
specimens; those which are recommended must have 
the highest relative sensitivities and specificities. They 
include mostly enzyme immunoassay (EIA), 
particularly the late generation of enzyme-linked 
immunosorbent assays (9, 10). Commercially 
available tests are based on the detection of wild-type 
and mutant HBsAg. The specificity of HBsAg enzyme 
immunoassays is over 99%: false positive results 





samples, with haemoglobin or bilirubin). Higher rates 
of false positive results are observed during 
pregnancy than in the general population. False 
negative or atypical results are also observed under 
several circumstances, including S (surface) gene 
mutants and variants in HBV, and HCV co-infection 
which may interfere with HBV replication and/or 
HBsAg expression (10). To avoid such situations, two 
different assays have been used in certain studies for 
HBsAg screening in pregnant women, the second test 
to “affirm” the results found with the first (7, 11). 
However, confirmation assays were not used more 
often. These immunoassays failure to detect HBsAg 
could impact as well the epidemiological studies as 
the diagnosis of HBV infection, and therefore 
compromise national programs against viral hepatitis 
B if an appropriate screening algorithm is not used.  
The aim of this study was to determine the current 
prevalence of HBV infection and to re-examine the 
epidemiology of HBV infection among pregnant 
women in Burkina Faso. 
 
MATERIALS AND METHODS  
Study population and settings 
The population of study was constituted of pregnant 
women from whom the annual seroprevalence of HIV 
is determined in Burkina Faso, according to the 
UNAIDS/WHO guidelines. The Review Board of the 
University teaching Hospital “CHU Yalgado 
Ouedraogo” and the National Ethics Committee 
approved the study. It was carried out under 
anonymous conditions. The Demographic data were 
recorded using a structured questionnaire, and the 
blood samples were collected with the voluntary 
consent of each pregnant woman.  
  
Sample collection and laboratory procedures 
Blood sample were collected from 1139 pregnant 
women in three medical centres, CMA Saint Camille, 
CMA Kossodo and CMA Schiphra in Ouagadougou, 
from October 2006 to January 2007. After 
centrifugation, sera were aliquoted and stored at –
20°C until assays were performed. Each sample was 
tested for HBsAg by two enzyme linked 
immunoassays: Hepanostika®HBsAg Uniform II B9 
(Bio-Mérieux; France) and Abbott HBsAg (V2) 
AxSYM® system (Abbott Diagnostics; Germany), 
according to their manufacturer instructions. Then, all 
the positive samples were tested with a confirmatory 
neutralization assay, Hepanostika®HBsAg Uniform II 
B9 Confirmatory (Bio-Merieux). 
 
Statistical analysis 
The Epi Info 2004 version 3.3 software was used to 
record all the sociodemographic data and the results 
of the serological assays. Comparisons between 
variables were done using the Chi-2 test. Statistically 




Characteristics of pregnant women 
A total of 1139 pregnant women aged from 15 to 45 
years, on prenatal visits, were enrolled from three 
centres in Ouagadougou. Their mean age was 
24.8±5.7 years [15-45years of age]. Among them, 
54.1% were less than 25 years old, 79.5% were less 
than 30 years old, 13% were and only 1.7% were more 
than 40 years old (Table 1).  
 
HBsAg prevalence without neutralization 
confirmatory assay 
Among the1139 non repetitive samples which were 
tested, 238 (20.9%) were HBsAg+ with one or with 
both screening tests simultaneously (Figure 1). Of 
these 1139 samples, the Hepanostika® HBsAg 
Uniform II B9 assay detected 193 (16.9%) HBsAg-
positive versus 138 (12.1%) with Abbott HBsAg (V2) 
AxSYM system assay and this difference was 
statistically significant (P=0.0001; OR=18.621; 95%CI: 
12.33-28.10). 
The distribution of the pregnant women HBsAg-
positive according to the age ranges is reported in 
table1. The results showed that all the age ranges 
were affected; the rates were higher with both assays 
in the age ranges of 25-29 years than in the other age 
groups. However, the differences between the age 
ranges were not statistically significant neither with 
Hepanostika® HBsAg Uniform II B9 assay (P=0.31), 
nor with Abbott HBsAg (V2) AxSYM system assay 
(P=0.19).   
 
HBsAg+ rate in pregnant women after 
neutralization confirmatory assay 
Hundred and three (9%) samples were HBsAg-
positive after the confirmatory assay. In comparison 
with the rate found with the two screening assays 
(20.9%), this difference represented 56.7% of false 
negative results, globally. Discordant results were 
found as well between the confirmation assay and 
Hepanostika®HBsAg Uniform II B9 with 90 samples 
(54 false positives and 19 false negatives), as with 
Abbott HBsAg (V2) AxSYM system (90 false 
positives). After confirmation, the rate of HBsAg-
positive samples was lower than those found with 
Hepanostika®HBsAg Uniform II B9 or HBsAg (V2) 
AxSYM system (P<0.0001; OR: 80.398; 95%CI: 45.54-
141.92). The analysis of the results after confirmation, 
according to the age, showed also that the rates of 
HBsAg-positive pregnant women were also higher in 




Hepatitis B surface antigen (HBsAg) in the serum is 
the most commonly used marker to indicate ongoing 
infection with HBV which may be completely 
asymptomatic. In this study, it was detected in 
pregnant women with two assays at the same time, 
but without physical exams to detect clinical hepatitis. 
The rate of 20.9% obtained with one or with both 
screening tests simultaneously, but without 
confirmation assay, showed that Burkina Faso 
belongs to the hyperendemic area for HBsAg. 





previous studies in Burkina Faso, as well in 
Ouagadougou (11-14), as in other urban or rural areas 
(12, 15).   Two different tests were used in some of 
these studies to screen HBsAg (11, 13, 14), while only 
one test was used in the others (12, 15). In the studies 
in which used a single screening test, the reported 
prevalences seemed higher (8.3%-24.1%) than those 
reported in the works which used two different tests 
to screen the HBsAg (9.3%-11.5%). Only one of these 
studies used a confirmatory assay, with a final  
 
 
TABLE 1: RATE OF HBS-POSITIVE PREGNANT WOMEN BEFORE AND AFTER CONFIRMATION ASSAY 




Total tested Hepanostika® HBsAg Uniform II 
B9  
(Bio-Mérieux) 
HBs Ag (V2) AxSYM system 
(Abbott Diagnostics) 
Hepanostika®HBsAg UniformII 
Confirmatory (Bio-Merieux ) 
Number % HBsAg+ (%) HBsAg– (%) HBsAg+ (%) HBsAg– (%) HBsAg+ (%) HBsAg– (%) 
15-19 195 (17.1) 33(16.9) 162 (83.1) 23 (11.8) 172 (88.2) 17 (8.7) 178 (91.3) 
20-24 421 (37) 68 (16.2) 353 (83.8) 44 (10.5) 377 (89.5) 34 (8.1) 387 (91.9) 
25-29 289 (25.4) 60 (20.8) 229 (79.2) 48 (16.6) 241 (83.4) 32 (11.1) 257 (88.9) 
30-34 148 (13) 18 (12.2) 130 (87.8) 15 (10.1) 133 (89.9) 11 (7.4) 137 (92.6) 
35-39 66 (5.8) 10 (15.2) 56 (84.8) 6 (9.1) 60 (90.9) 7 (10.6) 59 (89.4) 
≥40 20 (1.8) 4 (20) 16 (80) 2 (10) 18 (90) 2 (10) 18 (90) 
Total 1139 (100) 193 (16.9) 946 (83.1) 138 (12.1) 1001 (87.9) 103 (9) 1036 (91) 
 
prevalence of 11.5% (14). All these studies could 
suffer from bias in the definition of study 
populations. Besides, the used commercial kits were 
not identical in all these studies, and the algorithms 
were different.  
Despite the high performance of the HBsAg screening 
assays, “false” results are still reported (10). After the 
confirmation assay in this study in Burkina Faso, the 
rate of HBsAg-positive pregnant women decreased 
from 20.9% to 9%. Nineteen false positive samples 
were found with Abbott HBsAg (V2) AxSYM system 
assay. The causes of false-negative might be various, 
including the HBsAg level below the detection limit 
in chronic HBV carriers, either or not combined with 
mutations, the presence of variants that are not 
recognized by the antibodies used in the screening 
assay, or immune complexes masking HBsAg 
epitopes (10, 16). No false negative sample was found 
with Hepanostika®HBsAg Uniform II B9 assay. 
However, there were 90 false positive samples with 
Hepanostika®HBsAg Uniform II B9 assay and 54 with 
HBs Ag (V2) AxSYM system. Nevertheless, according 
to an epidemiological approach, the various results 
obtained had no impact on the belonging of Burkina 
Faso to a hyperendemic area of hepatitis B virus 
infections.  
In acute viral hepatitis B, HBsAg is present during 
less than 6 months in the blood of infected persons. In 
chronic forms of the infection, HBsAg remains 
detectable in the serum for period of time longer than 
6 months, and sometimes indefinitely. However, 
HBsAg can become undetectable when natural or 
acquired mutations occur in the genes which code for 
HBsAg (10, 17, 18): these cases include the viral 
hepatitis B occult which is defined by the presence of 
HBV DNA in the serum or liver of people without 
HBsAg (19). Former studies had reported that 
selection of HBsAg mutants were a rare event and 
their prevalence in the population of HBV-infected 
patients remained relatively low, even in highly 
endemic areas, despite extensive immunization which 
had not favored the emergence of HBsAg variant 
viruses (20). However Chemin and Trepo (21) showed 
that the prevalence of cryptogenic hepatitis varies 
widely among the published studies and that 
evidence is accumulating that occult HBV infections 
are widespread in many geographic areas. How such 
forms can impact the epidemiology of HBV in 
Burkina Faso is unknown to our knowledge, because 
no data is available on occult hepatitis in the country.   
In a clinical approach of the disease in individuals, the 
accuracy and the reliability of assays are fundamental 
since the results are used either to monitor the disease 
in patients, or/and to protect non-infected people. In 
such cases, false results must be excluded as much as 
possible. Using only one and even two assays to 
screen HBsAg, without a confirmation assay could 
appear insufficient. Confirmatory assays are 
necessary to enhance the overall quality of HBsAg 
screening assay (22). Taking in account the cases of 
occult hepatitis, HBsAg detection alone could be 
insufficient also, as highly accurate the assay(s) used 
can be. An HBV screening algorithm that includes 





able to reveal occult hepatitis, especially in situations 
where HBV DNA detection by nucleic acid 
amplification technology is not implemented (6, 10, 
17). 
The results found in this study in Burkina Faso 
showed that the difference between the HBsAg 
screening assays and the confirmation assay was 
statistically significant. This difference could not 
impact data used to classify countries in epidemic 
areas of HBsAg carriage. However, in clinical and the 
immunization assessment contexts, it could be 
important to confirm the results of HBsAg screening 
testing by a neutralization assay.  To take the cryptic 
hepatitis as occult hepatitis B cases in account, it 
appears essential to detect other markers like anti-
HBc, mainly in settings where HBV nucleic acid 
amplification assays are not available. The 
immunization of newborns against hepatitis B was 
implemented in Burkina Faso on January 2006. In the 
future, the detection of HBsAg alone should be 
insufficient to assess the HBV prevalence in the 
country.  But already, an accurate screening or 
diagnostic of the viral hepatitis B according to the 
actual algorithms require a confirmation assay. 
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